Understanding the role of HPV in Cervical Cancer

Human papillomavirus is responsible for 99 percent of all cervical cancer


Two specific types, HPV 16 and HPV18, account for 70 percent of these cases.1,2

In ATHENA, the largest-ever study of cervical cancer screening practices, more than 47,000 women were tested for high-risk HPV types using the cobas® HPV Test. The study proved that HPV screening was more effective than Pap tests in both detecting and predicting high-grade cervical disease.

Roche is committed to helping change the standard of HPV screening to give women everywhere the best chance to prevent cervical cancer.

Infographic: Understanding the role of HPV in cervical cancer

Latest related news

New Professional Guidelines Recognize Benefit of Genotyping HPV 16 and 18 for Cervical Cancer Prevention by Assessing Individual Patient Risk

Pleasanton, California, March 15, 2012

Evidence to support DNA genotyping for HPV as a co-testing approach provided by Roche’s landmark ATHENA study



  1. Division of STD Prevention. Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants’ Meeting. Department of Health and Human Services, Atlanta: Centers for Disease Control and Prevention (CDC), December 1999. Accessed May 13, 2016.
  2. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645–2654.